A systematic review of the cost-effectiveness of recombinant factor VIIa (rFVIIa) and activated prothrombin complex concentrate (aPCC) in the treatment of mild to moderate bleeding episodes for haemophilia patients with inhibitors

Chris Knight, Williams House, RTI Health Solutions, Manchester, United Kingdom; Novo Nordisk A/S, Sorgenfri, Denmark; KMHO, Brighton, United Kingdom

Blood. 2008;112((11):): Abstract No. 4678.
Study details
Study Design : Economic Study